Unveiling the Therapeutic Potential of Isoliquiritigenin in Prostate Cancer: Insights from a Systematic Review and Meta-Analysis
Abstract
Background: Prostate cancer is a significant and primary cause of cancer-related mortality among men worldwide with treatment challenges that include resistance to conventional therapies. Isoliquiritigenin (ISL) is a natural compound with anticancer properties which have emerged as a potential alternative.
Purpose: This review explores the role of ISL in prostate cancer treatment by analyzing preclinical and clinical studies.
Methodology: The relevant studies investigating the anticancer effect of ISL were identified using a systematic literature review across PubMed, Scopus, Web of Science, and Google Scholar. Depending on the inclusion and exclusion criteria, the studies were screened and data was extracted regarding tumor growth inhibition, sample size, molecular pathways, etc. Quality assessment was performed with the Newcastle-Ottawa Scale (NOS), and the pooled data was analyzed using I² statistics to examine the potential of ISL as a treatment for prostate cancer.
Results: A sum of 8 studies were included which met the criteria for meta-analysis. It demonstrated the anti-proliferative effects that induce apoptosis via depolarization in the mitochondrial membrane and the activation of caspase-3. The cell cycle halts at the G1 and G2/M phases by influencing p21 and p27. It also serves as a possible chemosensitizing agent.
Conclusion: ISL shows anticancer properties through various mechanisms. It is recommended that ISL be used in combination therapies to address drug resistance. Further in vivo and clinical studies are needed to evaluate and assess the drug profile of ISL in human models.
Keywords: Isoliquiritigenin, Prostate cancer, Apoptosis, Cell cycle arrest
Keywords:
Isoliquiritigenin, Prostate cancer, Apoptosis, Cell cycle arrestDOI
https://doi.org/10.22270/jddt.v15i10.7406References
1. Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S.Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules, 2022,27(17):5730 https://doi.org/10.3390/molecules27175730
2. Zhang Z, Yung KK, Ko JK. Therapeutic intervention in cancer by isoliquiritigenin from licorice: a natural antioxidant and redox regulator. Antioxidants (Basel),2022, 11(7):1349. https://doi.org/10.3390/antiox11071349
3. Klempner, S. J, & Bubley G. Complementary and alternative medicines in prostate cancer: from bench to bedside. The oncologist,2012, 17(6), 830–837. https://doi.org/10.1634/theoncologist.2012-0094
4. Hussar, P . Apoptosis regulators bcl-2 and caspase-3. Encyclopedia ,2022, 2, 1624-1636. https://doi.org/10.3390/encyclopedia2040111
5. Westaby D, Jiménez-Vacas JM, Figueiredo I, Rekowski J, Pettinger C et al. BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity. J Clin Invest,2024,134(18): e179998. https://doi.org/10.1172/JCI179998
6. Hashemi M, Taheriazam A, Daneii P, Hassanpour A, Kakavand A et al. Targeting PI3K/Akt signaling in prostate cancer therapy. J Cell Commun Signal,2023, (3):423-443 https://doi.org/10.1007/s12079-022-00702-1
7. Siskin M, Economides, M. P, & Wise, D. R. Cyclin-dependent kinase inhibition in prostate cancer: past, present, and future; Cancers,2025, 17(5), 774. https://doi.org/10.3390/cancers17050774
8. Wang C, Huang S B, Yang, M C, Lin, Y T, et al. Combining paclitaxel with ABT-263 has a synergistic effect on paclitaxel resistant prostate cancer cells; PloS one,2015, 10(3), e0120913. https://doi.org/10.1371/journal.pone.0120913
9. Habib T N, Altonsy, M O, Ghanem, S A, Salama, et al. Optimizing combination therapy in prostate cancer: mechanistic insights into the synergistic effects of Paclitaxel and Sulforaphane-induced apoptosis. BMC molecular and cell biology,2024, 25(1), 5. https://doi.org/10.1186/s12860-024-00501-z
10. He Y, Sun, M.M, Zhang, G.G. et al . Targeting PI3K/Akt signal transduction for cancer therapy. Sig Transduct Target Ther,2021, 6, 425 ; https://doi.org/10.1038/s41392-021-00828-5
11. Obasaju C, & Hudes, G R. Paclitaxel and docetaxel in prostate cancer. Hematology/oncology clinics of North America,2001, 15(3), 525–545. https://doi.org/10.1016/s0889-8588(05)70230-6
12. Asnaashari S, Amjad E & Sokouti B. Synergistic effects of flavonoids and paclitaxel in cancer treatment: a systematic review: Cancer Cell Int;23,2023, 211 https://doi.org/10.1186/s12935-023-03052-z
13. Lodi A, Saha A, Lu X, Wang B, Sentandreu E, Collins M, et al., Combinatorial treatment with natural compounds in prostate cancer inhibits prostate tumor growth and leads to key modulations of cancer cell metabolism. NPJ Precis Oncol,2017, 1:18 https://doi.org/10.1038/s41698-017-0024-z
14. Arena, A Romeo, M A Benedetti, R Masuelli, L Bei, R Gilardini Montani, M S Cirone. New insights into curcumin- and resveratrol-mediated anti-cancer effects Pharmaceuticals (basel, switzerland),2021, 14(11), 1068. https://doi.org/10.3390/ph14111068
15. Basak, D Gregori, L Johora, F Deb, S. Preclinical and clinical research models of prostate cancer: a brief overview. Life 2022;12, 1607. https://doi.org/10.3390/life12101607
16. Abate-Shen, C & Nunes de Almeida, F Establishment of the lncap cell line - the dawn of an era for prostate cancer research. Cancer research,2022, 82(9), 1689–1691. https://doi.org/10.1158/0008-5472.CAN-22-1065
17. Wang, K L, Yu, Y C Hsia, S M. Perspectives on the role of isoliquiritigenin in cancer. Cancers,2021, 13, 115. https://doi.org/10.3390/cancers13010115
18. Adamiecki, R Hryniewicz-Jankowska, A Ortiz, M. A Li, X Porter-Hansen, B. A Nsouli et al. In vivo models for prostate cancer research. Cancers,2022 14(21), 5321. https://doi.org/10.3390/cancers14215321
19. Jung, JI, Chung, E Seon, M R Shin, H K Kim, E J Lim et al. Isoliquiritigenin (ISL) inhibits erbB3 signaling in prostate cancer cells. BioFactors (Oxford, England),2006, 28(3-4), 159–168 https://doi.org/10.1002/biof.5520280302
20. Zhang, B Lai, Y Li, Y Shu, N Wang, Z Wang, et al. Antineoplastic activity of isoliquiritigenin, a chalcone compound, in androgen-independent human prostate cancer cells linked to G2/M cell cycle arrest and cell apoptosis. European journal of pharmacology,2018, 821, 57–67. https://doi.org/10.1016/j.ejphar.2017.12.053
21. Lee, Y. M Lim, D. Y Choi, H J Jung, J I Chung, W Y & Park, J H. Induction of cell cycle arrest in prostate cancer cells by the dietary compound isoliquiritigenin. Journal of medicinal food ,2008,12(1), 8–14. https://doi.org/10.1089/jmf.2008.0039
22. Jung JI, Lim, S S Choi, H J Cho, H J Shin, H K Kim. Isoliquiritigenin induces apoptosis by depolarizing mitochondrial membranes in prostate cancer cells. The Journal of nutritional biochemistry,2006, 17(10), 689–696. https://doi.org/10.1016/j.jnutbio.2005.11.006
23. Huang, Y Liu, C Zeng, W C Xu, G Y Wu, J M Li, et al. Isoliquiritigenin inhibits the proliferation, migration and metastasis of Hep3B cells via suppressing cyclin D1 and PI3K/AKT pathway. Bioscience reports,2020, 40(1), BSR20192727. https://doi.org/10.1042/BSR20192727
24. Kanazawa, M Satomi, Y Mizutani, Y Ukimura, O Kawauchi, A Sakai. Isoliquiritigenin inhibits the growth of prostate cancer. European urology,2003, 43(5), 580–586. https://doi.org/10.1016/s0302-2838(03)00090-3
25. Zhang X, Yeung ED, Wang J, Panzhinskiy EE, Tong C, Li W et al. Isoliquiritigenin, a natural anti-oxidant, selectively inhibits the proliferation of prostate cancer cells. Clin Exp Pharmacol Physiol,2010, 37(8):841-7 https://doi.org/10.1111/j.1440-1681.2010.05395.x
26. Haddad, A Q Venkateswaran, V Viswanathan, L Teahan, S. J Fleshner, et al. Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell lines. Prostate cancer and prostatic diseases,2006, 9(1), 68–76. https://doi.org/10.1038/sj.pcan.4500845
27. Jung JI, Lim, S. S Choi, H. J Cho, H. J Shin, H. K Kim. Isoliquiritigenin induces apoptosis by depolarizing mitochondrial membranes in prostate cancer cells. The Journal of nutritional biochemistry,2006, 17(10), 689–696. https://doi.org/10.1016/j.jnutbio.2005.11.006
28. Qian, S Wei, Z Yang, W Huang, J Yang, Y & Wang, J. The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Frontiers in oncology,2022, 12, 985363. https://doi.org/10.3389/fonc.2022.985363
29. Philipp Wolf, Axel Schoeniger, Frank Edlich.Pro-apoptotic complexes of BAX and BAK on the outer mitochondrial membrane,Biochimica et Biophysica Acta (BBA) - Molecular Cell Research,2022, 1869(10),119317,ISSN 0167-4889, https://doi.org/10.1016/j.bbamcr.2022.119317.
30. Shin, D Y Kim, G Y Lee, J H Choi, B T Yoo, Y. H & Choi, Y H. Apoptosis induction of human prostate carcinoma DU145 cells by diallyl disulfide via modulation of JNK and PI3K/AKT signaling pathways. International journal of molecular sciences,2012, 13(11), 14158–14171. https://doi.org/10.3390/ijms131114158.
31. Cifuentes, E Croxen, R Menon, M Barrack, E. R & Reddy, G. P. Synchronized prostate cancer cells for studying androgen regulated events in cell cycle progression from G1 into S phase. Journal of cellular physiology,2003, 195(3), 337–345. https://doi.org/10.1002/jcp.10317
32. Al Bitar S & Gali-Muhtasib. The role of the cyclin dependent kinase inhibitor p21cip1/waf1 in targeting cancer: molecular mechanisms and novel therapeutics. Cancers,2019,11(10), 1475. https://doi.org/10.3390/cancers11101475
33. Hsu, Y L Kuo, P L& Lin, C C. Isoliquiritigenin induces apoptosis and cell cycle arrest through p53-dependent pathway in Hep G2 cells. Life sciences,2005, 77(3), 279–292. https://doi.org/10.1016/j.lfs.2004.09.047
34. Zhong, W, & Sun, T. Epithelial-mesenchymal transition (EMT) as a therapeutic target in cancer,. Frontiers in oncology, volume II 13,2023, 1218855. https://doi.org/10.3389/fonc.2023.1218855
35. Domenico Ribatti, Roberto Tamma, Tiziana Annese. Epithelial-mesenchymal transition in cancer: a historical overview,Translational oncology,2020, 13(6);100773,1936-5233, https://doi.org/10.1016/j.tranon.2020.100773.
36. Parra E. . Inhibition of JNK-1 by small interfering RNA induces apoptotic signaling in PC-3 prostate cancer cells. International journal of molecular medicine,2012, 30(4), 923–930. https://doi.org/10.3892/ijmm.2012.1055
37. McEleny, K R Watson, R W Coffey, R N O'Neill, A J & Fitzpatrick, J M.Inhibitors of apoptosis proteins in prostate cancer cell lines. The Prostate,2002, 51(2), 133–140. https://doi.org/10.1002/pros.10061
38. Li, C Cheng, D & Li, P. Androgen receptor dynamics in prostate cancer: from disease progression to treatment resistance. Frontiers in oncology,2025, 15, 1542811. https://doi.org/10.3389/fonc.2025.1542811
39. Yang, Q Fung, KM Day, W.V. et al. Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival. Cancer Cell Int2005; 5, 8 https://doi.org/10.1186/1475-2867-5-8
40. Molter, C. W Muszynski, E F Tao, Y Trivedi, T Clouvel, A., & Ehrlicher, A. J. Prostate cancer cells of increasing metastatic potential exhibit diverse contractile forces, cell stiffness, and motility in a microenvironment stiffness-dependent manner. Frontiers in cell and developmental biology,2022, 10, 932510. https://doi.org/10.3389/fcell.2022.932510
41. Puente J, Grande E, Medina A, Maroto P, Lainez N, Arranz JA. Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting. ther adv Med Oncol,2017, 9(5):307-318. https://doi.org/10.1177/1758834017692779
42. Lee SH, Lee YJ. Synergistic anticancer activity of resveratrol in combination with docetaxel in prostate carcinoma cells. Nutr Res Pract,2021,.15(1):12-25. https://doi.org/10.4162/nrp.2021.15.1.12
43. Huang, Y Hong, W. & Wei, X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol 15,2022, 129 https://doi.org/10.1186/s13045-022-01347-8
44. Guo, Q Jin, Y Chen, X Ye, X Shen, X Lin et al. NF-κB in biology and targeted therapy: new insights and translational implications. Signal transduction and targeted therapy,2024, 9(1), 53. https://doi.org/10.1038/s41392-024-01757-9
45. Wang, K L Yu, Y C, & Hsia, S. M. Perspectives on the role of isoliquiritigenin in cancer. Cancers,2021, 13(1), 115. https://doi.org/10.3390/cancers13010115
46. Lee, Y K Chin, Y W Bae, J K Seo, J. S & Choi, Y. H. Pharmacokinetics of isoliquiritigenin and its metabolites in rats: low bioavailability is primarily due to the hepatic and intestinal metabolism. Planta medica,2013, 79(17), 1656–1665. https://doi.org/10.1055/s-0033-1350924
Published
Abstract Display: 169 
PDF Downloads: 125 PDF Downloads: 19 How to Cite
Issue
Section
Copyright (c) 2025 V Dhanshika , S Manisha, M Roshini , D Ragavarshini , K Dhivya
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.